DOCSLIB.ORG

Phenotypes of Dyslipidemia Disclosures

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phenotypes of Dyslipidemia Disclosures 5/2/15 Phenotypes of Dyslipidemia A mechanis8c approach to management John P. Kane, M.D., Ph.D. Professor of Medicine University of California, San Francisco Disclosures • Consultant FGH • Research Funding Synageva, Inc. 1 5/2/15 Phenotypes of Dyslipidemia ² Mechanis8c understanding leads to correct diagnosis ² Iden8ficaon of secondary gene8c mechanisms is important ² Treatment selec8on is based on phenotype Metabolism of VLDL and LDL Liver Capillary Lipoprotein wall Parenchymal Cell Lipase Golgi B-100 apparatus C TG C C VLDL C Receptor TG Lysosome B-100 CE Peripheral Remnant Cell CE B-100 Lysosome LDL Receptor 2 5/2/15 VERY HIGH TRIGLYCERIDES ² Primary causes: Impairment of lipoprotein lipase, ApoC-II, ApoA-V, LMF-1, GPIHBP, inhibi8on by Apo C-III ² Secondary Causes: Ø Insulin deficiency Ø Gammopathies, monoclonal and polyclonal ² Risk: Acute pancrea8s ² Management: Very low fat diet, no IV fat emulsions MODERATELY ELEVATED TRIGLYCERIDES WITH NORMAL LDL ² Primary Causes: Gene8c disorders of moderate severity ² Secondary causes: Diabetes, obesity, alcohol, sepsis, HIV, nephrosis, medicaons, gammopathies, lipodystrophy ² Risk: Arteriosclerosis, fay liver ² Management: PPAR alpha agonists, niacin, omega3, decrease alcohol, treat diabetes, obesity 3 5/2/15 Metabolism of VLDL and LDL Liver Capillary Lipoprotein wall Parenchymal Cell Lipase Golgi B-100 apparatus C TG C C VLDL C Receptor TG Lysosome B-100 CE Peripheral Remnant Cell CE B-100 Lysosome LDL Receptor Combined Hyperlipidemia ² Primary Cause: Unknown, highly penetrant gene8c factors. ² Prevalence: 1-2 percent of North American populaon. ² Risk: High risk of atherosclerosis ² Management: Drug combinaons, stans, Zea plus PPAR alpha agonists ² Treat: Diabetes, obesity 4 5/2/15 Metabolism of VLDL and LDL Liver Capillary Lipoprotein wall Parenchymal Cell Lipase Golgi B-100 apparatus C TG C C VLDL C Receptor TG Lysosome B-100 CE Peripheral Remnant Cell CE B-100 Lysosome LDL Receptor DYSBETALIPOPROTEINEMIA (Accumulaon of remnant lipoproteins) ² Cause: Homozygous Apo E-2, or other ligand-incompetent Apo E ² Risk: Arteriosclerosis, aor8c aneurysm ² Management: Stans, niacin 5 5/2/15 Metabolism of VLDL and LDL Liver Capillary Lipoprotein wall Parenchymal Cell Lipase Golgi B-100 apparatus C TG C C VLDL C Receptor TG Lysosome B-100 CE Peripheral Remnant Cell CE B-100 Lysosome LDL Receptor ISOLATED ELEVATION OF LDL ² Gene8c Causes: 1) Familial hypercholesterolemia 2) Ligand defec8ve hypercholesterolemia 3) Autosomal recessive hypercholesterolemia 4) PCSK9 gain of func8on mutaons ² Secondary causes: Hypothyroidism, gammopathies, early nephrosis, cholestasis ² Risk: Arteriosclerosis ² Management: Stans, Zea, niacin, (PCSK9, MTP inhibi8on) 6 5/2/15 HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ² Causes: Gene8c ² Risk: Very aggressive arteriosclerosis ² Management: Stan, if any receptor ac8vity; Zea, apheresis, an8sense RNA vs apoB-100, MTP inhibi8on Phytosterolemia ² Cause: Gene8c defects in plant sterol transporter (ABCG5, ABCG8) ² Risk: Arteriosclerosis ² Management: Zea, low phytosterol diet 7 5/2/15 Lp(a) Lipoprotein NH2 Protease n s X s IV IV IV V Apo B-100 … ELEVATED Lp(a) ² Causes: Gene8c ² Secondary: Hypothyroidism, inflammaon (nephrosis) ² Risk: Arteriosclerosis ² Management: ASA, reduce LDL, niacin, (PCSK9 inhibion) 8 5/2/15 LDL DEFICIENCY Abetalipoproteinemia: ² Gene8c cause: Mutaons in MTP ² Risk: Tocopherol deficiency, re8nal and neuropathic disorders Hypobetalipoproteinemia: ² Gene8c causes: Mutaons in ApoB-100, other ² Gammopathies ² Management: Moderate tocopherol supplementaon HYPOALPHALIPOPROTEINEMIA HDL DEFICIENCY ² Primary causes: Ø Tangier Disease Ø Lecithin-cholesterol acyl transferase deficiency Ø Mutaons in Apo A-I, other ² Secondary: Gammopathy, leukemia, (high triglycerides) ² Risk: Arteriosclerosis ² Management: Some cases respond to niacin 9 5/2/15 PreBeta-1 HDL Metabolism A-I Large CETP Chylos spherical VLDL (alpha) HDL IDL LDL LCAT A-I ABCA1 Transporter Free Cholesterol SR-BI Peripheral Cell Liver PLTP A-I Removal and degradaDon De novo synthesis of apo A-I Preβ -1 HDL liver and intesne A-I 10 .
Load more

Recommended publications
  • Genetic Testing for Familial Hypercholesterolemia AHS – M2137
    Corporate Medical Policy Genetic Testing for Familial Hypercholesterolemia AHS – M2137 File Name: genetic_testing_for_familial_hypercholesterolemia Origination: 01/01/2019 Last CAP Review: 07/2021 Next CAP Review: 07/2022 Last Review: 07/2021 Description of Procedure or Service Definitions Familial hypercholesterolemia (FH) is a genetic condition that results in premature atherosclerotic cardiovascular disease due to lifelong exposure to elevated low-density lipoprotein cholesterol (LDL-C) levels (Sturm et al., 2018). FH encompasses multiple clinical phenotypes associated with distinct molecular etiologies. The most common is an autosomal dominant disorder caused by mutations in one of three genes, low-density lipoprotein receptor (LDLR), apolipoprotein B-100 (APOB), and proprotein convertase subtilisin-like kexin type 9 (PCSK9) (Ahmad et al., 2016; Goldberg et al., 2011). Rare autosomal recessive disease results from mutation in low-density lipoprotein receptor adaptor protein (LDLRAP) (Garcia et al., 2001). Related Policies Cardiovascular Disease Risk Assessment AHS – G2050 ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician. Policy BCBSNC will provide coverage for genetic testing for familial hypercholesterolemia when it is determined the medical criteria or reimbursement guidelines below are met. Benefits Application This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy. When Genetic Testing for Familial Hypercholesterolemia is covered 1. Genetic testing to establish a molecular diagnosis of Familial Hypercholesterolemia is considered medically necessary when BOTH of the following criteria are met: A.
    [Show full text]
  • Lipodystrophy Due to Adipose Tissue Specific Insulin Receptor
    Page 1 of 50 Diabetes Lipodystrophy Due to Adipose Tissue Specific Insulin Receptor Knockout Results in Progressive NAFLD Samir Softic1,2,#, Jeremie Boucher1,3,#, Marie H. Solheim1,4, Shiho Fujisaka1, Max-Felix Haering1, Erica P. Homan1, Jonathon Winnay1, Antonio R. Perez-Atayde5, and C. Ronald Kahn1. 1 Section on Integrative Physiology and Metabolism, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 2 Division of Gastroenterology, Hepatology and Nutrition, Boston Children’s Hospital, Boston, MA 3 Cardiovascular and Metabolic Diseases iMed, AstraZeneca R&D, 431 83 Mölndal, Sweden (current address) 4 KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway 5 Department of Pathology, Boston Children’s Hospital, and Harvard Medical School, Boston, MA # These authors contributed equally to this work. Corresponding author: C. Ronald Kahn, MD Joslin Diabetes Center One Joslin Place Boston, MA 02215 Phone: (617)732-2635 Fax:(617)732-2487 E-mail: [email protected] Keywords: Insulin receptors, IGF-1 receptors, lipodystrophy, diabetes, dyslipidemia, fatty liver, liver tumor, NAFLD, NASH. Running title: Lipodystrophic mice develop progressive NAFLD 1 Diabetes Publish Ahead of Print, published online May 10, 2016 Diabetes Page 2 of 50 SUMMARY Ectopic lipid accumulation in the liver is an almost universal feature of human and rodent models of generalized lipodystrophy and also is a common feature of type 2 diabetes, obesity and metabolic syndrome. Here we explore the progression of fatty liver disease using a mouse model of lipodystrophy created by a fat-specific knockout of the insulin receptor (F-IRKO) or both IR and insulin-like growth factor-1 receptor (F- IR/IGF1RKO).
    [Show full text]
  • Commonly Used Lipidcentric ICD-10 (ICD-9) Codes
    Commonly Used Lipidcentric ICD-10 (ICD-9) Codes *This is not an all inclusive list of ICD-10 codes R.LaForge 11/2015 E78.0 (272.0) Pure hypercholesterolemia E78.3 (272.3) Hyperchylomicronemia (Group A) (Group D) Familial hypercholesterolemia Grütz syndrome Fredrickson Type IIa Chylomicronemia (fasting) (with hyperlipoproteinemia hyperprebetalipoproteinemia) Hyperbetalipoproteinemia Fredrickson type I or V Hyperlipidemia, Group A hyperlipoproteinemia Low-density-lipoid-type [LDL] Lipemia hyperlipoproteinemia Mixed hyperglyceridemia E78.4 (272.4) Other hyperlipidemia E78.1 (272.1) Pure hyperglyceridemia Type 1 Diabetes Mellitus (DM) with (Group B) hyperlipidemia Elevated fasting triglycerides Type 1 DM w diabetic hyperlipidemia Endogenous hyperglyceridemia Familial hyperalphalipoproteinemia Fredrickson Type IV Hyperalphalipoproteinemia, familial hyperlipoproteinemia Hyperlipidemia due to type 1 DM Hyperlipidemia, Group B Hyperprebetalipoproteinemia Hypertriglyceridemia, essential E78.5 (272.5) Hyperlipidemia, unspecified Very-low-density-lipoid-type [VLDL] Complex dyslipidemia hyperlipoproteinemia Elevated fasting lipid profile Elevated lipid profile fasting Hyperlipidemia E78.2 (272.2) Mixed hyperlipidemia (Group C) Hyperlipidemia (high blood fats) Broad- or floating-betalipoproteinemia Hyperlipidemia due to steroid Combined hyperlipidemia NOS Hyperlipidemia due to type 2 diabetes Elevated cholesterol with elevated mellitus triglycerides NEC Fredrickson Type IIb or III hyperlipoproteinemia with E78.6 (272.6)
    [Show full text]
  • Pathophysiology of Adipocyte Defects and Dyslipidemia in HIV Lipodystrophy: New Evidence from Metabolic and Molecular Studies
    American Journal of Infectious Diseases 2 (3): 167-172, 2006 ISSN 1553-6203 © 2006 Science Publications Pathophysiology of Adipocyte Defects and Dyslipidemia in HIV Lipodystrophy: New Evidence from Metabolic and Molecular Studies 1,6Ashok Balasubramanyam, 1,6Rajagopal V. Sekhar, 2,3Farook Jahoor 4Henry J. Pownall and 5Dorothy Lewis 1Translational Metabolism Unit, Division of Diabetes, Endocrinology and Metabolism, 2Department of Pediatrics, 3Children’s Nutrition Research Center 4Section of Atherosclerosis and Lipoprotein Metabolism, 5Department of Immunology Baylor College of Medicine; 6Endocrine Service, Ben Taub General Hospital, Houston, Texas Abstract: Despite a burgeoning mass of descriptive information regarding the epidemiology, clinical features, body composition changes, hormonal alterations and dyslipidemic patterns in patients with HIV lipodystrophy syndrome (HLS), the specific biochemical pathways that are dysregulated in the condition and the molecular mechanisms that lead to their dysfunction, remain relatively unexplored. In this paper, we review studies that detail the metabolic basis of the dyslipidemia - specifically, the hypertriglyceridemia - that is the serologic hallmark of HLS and present new data relevant to mechanisms of dyslipidemia in the postprandial state. We also describe preliminary experiments showing that in addition to the well-known effects of highly-active antiretroviral drugs, the functional disruption of adipocytes and preadipocytes by factors intrinsic to HIV-infected immunocytes may play a role in the pathogenesis of HLS. Key words: Triglycerides, cholesterol, lipoprotein lipase, lipolysis, lymphocyte INTRODUCTION Metabolic basis of HLS - studies in the fasting and fed state: Whole body kinetic studies have Characteristics of dyslipidemia and its relationship demonstrated defects in specific lipid metabolic [19-21] to lipodystrophy: A characteristic dyslipidemic pattern pathways in HLS patients in both the fasting and observed in the majority of patients with HLS is fed (25) states.
    [Show full text]
  • Lipoprotein Lipase: a General Review Moacir Couto De Andrade Júnior1,2*
    Review Article iMedPub Journals Insights in Enzyme Research 2018 www.imedpub.com Vol.2 No.1:3 ISSN 2573-4466 DOI: 10.21767/2573-4466.100013 Lipoprotein Lipase: A General Review Moacir Couto de Andrade Júnior1,2* 1Post-Graduation Department, Nilton Lins University, Manaus, Amazonas, Brazil 2Department of Food Technology, Instituto Nacional de Pesquisas da Amazônia (INPA), Manaus, Amazonas, Brazil *Corresponding author: MC Andrade Jr, Post-Graduation Department, Nilton Lins University, Manaus, Amazonas, Brazil, Tel: +55 (92) 3633-8028; E-mail: [email protected] Rec date: March 07, 2018; Acc date: April 10, 2018; Pub date: April 17, 2018 Copyright: © 2018 Andrade Jr MC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Citation: Andrade Jr MC (2018) Lipoprotein Lipase: A General Review. Insights Enzyme Res Vol.2 No.1:3 Abstract Lipoprotein Lipase: Historical Hallmarks, Enzymatic Activity, Characterization, and Carbohydrates (e.g., glucose) and lipids (e.g., free fatty acids or FFAs) are the most important sources of energy Present Relevance in Human for most organisms, including humans. Lipoprotein lipase (LPL) is an extracellular enzyme (EC 3.1.1.34) that is Pathophysiology and Therapeutics essential in lipoprotein metabolism. LPL is a glycoprotein that is synthesized and secreted in several tissues (e.g., Macheboeuf, in 1929, first described chemical procedures adipose tissue, skeletal muscle, cardiac muscle, and for the isolation of a plasma protein fraction that was very rich macrophages). At the luminal surface of the vascular in lipids but readily soluble in water, such as a lipoprotein [1].
    [Show full text]
  • Other Types of Primary Hyperlipoproteinemia
    82 Journal of Atherosclerosis and Thrombosis Vol.21, No.2 Committee Report 10 Other Types of Primary Hyperlipoproteinemia (Hyperlipidemia) Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan ― 2012 Version Tamio Teramoto, Jun Sasaki, Shun Ishibashi, Sadatoshi Birou, Hiroyuki Daida, Seitaro Dohi, Genshi Egusa, Takafumi Hiro, Kazuhiko Hirobe, Mami Iida, Shinji Kihara, Makoto Kinoshita, Chizuko Maruyama, Takao Ohta, Tomonori Okamura, Shizuya Yamashita, Masayuki Yokode and Koutaro Yokote Committee for Epidemiology and Clinical Management of Atherosclerosis 1. Primary Hyperlipoproteinemias (Hyperlipidemias) enhanced hepatic apolipoprotein (apo) B-100 synthe- Other Than Familial Hypercholesterolemia sis, decreased LPL activity, increased very-low-density There are various types of primary hyperlipopro- lipoprotein (VLDL) secretion from the liver and the teinemias (hyperlipidemias) other than familial hyper- accumulation of visceral fat as factors for the develop- cholesterolemia (FH). These types are clinically ment of symptoms and has been reported to be related important and classified according to their associated to abnormalities of the LPL and APOC-Ⅱ genes or pathophysiology and genetic abnormalities (Table 1)1). APOA-Ⅰ/C-Ⅲ/A-Ⅳ gene cluster. However, none of Familial lipoprotein lipase (LPL) deficiency manifests these findings have been proven to be definitive. It has as severe hyperchylomicronemia and may present with also been suggested that FCHL is caused by a poly- eruptive cutaneous xanthomas or acute pancreatitis, genic background that tends to induce hyperlipopro- although it does not necessarily accompany atheroscle- teinemia due to environmental factors, such as over- rotic cardiovascular disease (CVD). On the other nutrition and a low level of physical activity.
    [Show full text]
  • Evaluation and Treatment of Hypertriglyceridemia: an Endocrine Society Clinical Practice Guideline
    SPECIAL FEATURE Clinical Practice Guideline Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline Lars Berglund, John D. Brunzell, Anne C. Goldberg, Ira J. Goldberg, Frank Sacks, Mohammad Hassan Murad, and Anton F. H. Stalenhoef University of California, Davis (L.B.), Sacramento, California 95817; University of Washington (J.D.B.), Seattle, Washington 98195; Washington University School of Medicine (A.C.G.), St. Louis, Missouri 63110; Columbia University (I.J.G.), New York, New York 10027; Harvard School of Public Health (F.S.), Boston, Massachusetts 02115; Mayo Clinic (M.H.M.), Rochester, Minnesota 55905; and Radboud University Nijmegen Medical Centre (A.F.H.S.), 6525 GA Nijmegen, The Netherlands Objective: The aim was to develop clinical practice guidelines on hypertriglyceridemia. Participants: The Task Force included a chair selected by The Endocrine Society Clinical Guidelines Subcommittee (CGS), five additional experts in the field, and a methodologist. The authors received no corporate funding or remuneration. Consensus Process: Consensus was guided by systematic reviews of evidence, e-mail discussion, conference calls, and one in-person meeting. The guidelines were reviewed and approved sequen- tially by The Endocrine Society’s CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. Conclusions: The Task Force recommends that the diagnosis of hypertriglyceridemia be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150–999 mg/dl) be diagnosed to aid in the evaluation of cardiovascular risk, and that severe and very severe hyper- triglyceridemia (triglycerides of Ͼ 1000 mg/dl) be considered a risk for pancreatitis.
    [Show full text]
  • Familial Partial Lipodystrophy
    Familial Partial Lipodystrophy Purvisha Patel; Ralph Starkey, MD; Michele Maroon, MD The lipodystrophies are rare disorders character- ized by insulin resistance and the absence or loss of body fat. The 4 subtypes of lipodystrophy are characterized by onset and distribution. Partial lipodystrophy is rare, with loss of fat from the extremities and excess fat accumulation in the face and neck; recognizing this phenotype and subsequent referral for endocrinologic care may improve outcome and reduce mortality. ipodystrophies are rare disorders characterized by insulin resistance and the absence or L loss of body fat.1 Classification of the 4 main subtypes of lipodystrophy is based on onset (congenital/familial vs acquired/sporadic) and dis- Figure not available online tribution (total/generalized vs partial). Congenital total lipodystrophy (also known as Berardinelli syndrome, Seip syndrome) is a rare autosomal- recessive disorder marked by an almost complete lack of adipose tissue from birth. Familial partial lipodystrophy (also known as Kobberling-Dunnigan syndrome) involves loss of subcutaneous fat from the extremities and accumulation of excess fat in the face and neck and to a lesser extent in the hands and feet. Acquired total lipodystrophy (also known as lipoatrophy, Lawrence-Seip syndrome) presents with generalized loss of fat beginning in childhood. Acquired partial lipodystrophy (also known as progressive lipodystrophy, partial lipoat- Figure 1. Accentuation of fat pads in the face and neck. rophy, Barraquer-Simons syndrome) is character- ized by loss of fat only from the upper extremities, face, and trunk.2 tional uterine bleeding (gravida 2, para 1, AB 1) Case Report necessitating total hysterectomy. On physical A 39-year-old white woman presented with the examination, accentuation of fat pads in the face complaint of thickened brown skin on the neck and and neck (Figure 1), central obesity, and prominent medial thighs.
    [Show full text]
  • Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib
    Guidelines Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib Normand Blais 1,* , Jean-Philippe Adam 2 , John Nguyen 2 and Jean C. Grégoire 3 1 Service d’Hématologie-Oncologie, Département de Médicine, Centre Hospitalier de l’Université de Montréal (CHUM), Montréal, QC H2X 3E4, Canada 2 Département de Pharmacie, Centre Hospitalier de l’Université de Montréal (CHUM), Université de Montréal, Montréal, QC H2X 3E4, Canada; [email protected] (J.-P.A.); [email protected] (J.N.) 3 Département de Cardiologie, Institut de Cardiologie de Montréal, Montréal, QC H2X 3E4, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-514-890-8000 (ext. 25381); Fax: +1-514-412-7572 Received: 22 December 2020; Accepted: 23 December 2020; Published: 4 January 2021 Abstract: The use of lorlatinib, an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive metastatic non-small cell lung cancer, is associated with dyslipidemia in over 80% of patients. Clinical trial protocols for the management of lorlatinib-associated dyslipidemia differ from clinical practice guidelines for the management of dyslipidemia to prevent cardiovascular disease, in that they are based on total cholesterol and triglyceride levels rather than on the low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol levels that form the basis of current cardiovascular guideline recommendations. In order to simplify and harmonize the management of cardiovascular risk in patients with lorlatinib, an advisory committee consisting of a medical oncologist, a cardiologist, and two pharmacists with expertise in cardiology and oncology aimed to develop a simplified algorithm, adapted from the Canadian Cardiovascular Society dyslipidemia recommendations.
    [Show full text]
  • Late Ventricular Potentials in Familial Mediterranean Fever with and Without AA Amyloidosis Udi Nussinovitch1, Avi Livneh2,3
    DOI: 10.5152/eurjrheum.2017.16113 Original Article Late ventricular potentials in familial Mediterranean fever with and without AA amyloidosis Udi Nussinovitch1, Avi Livneh2,3 Abstract Objective: Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by episodic and chronic inflammation that may lead to both accelerated coronary atherosclerosis and cardiac AA amyloidosis. We hypothesized that late ventricular poten- tials (LPs), an established electrocardiographic susceptibility marker of ventricular arrhythmias, will be more common in FMF than in the adjusted normal population due to these two types of inflammation-associated cardiac effects. Therefore, we aimed to evaluate the occurrence of LPs in FMF patients with and without amyloidosis. Material and Methods: Signal-averaged electrocardiography was performed in consecutive patients with FMF using the Frank corrected orthogonal lead system. At least 200 consecutive beats were digitally recorded and averaged, and the presence of LPs was determined according to acceptable thresholds. Results: There were 54 patients with colchicine-treated FMF, of whom 14 had biopsy-proven AA amyloidosis. None of the uncom- plicated FMF patients and 2 of the 14 FMF amyloidosis patients had abnormal or borderline LPs. Conclusion: Based on LPs as a susceptibility marker for arrhythmia, FMF patients, including the large majority of FMF patients with amyloidosis, are seemingly not at an increased risk to develop arrhythmias. Keywords: AA Amyloidosis, familial Mediterranean fever, late ventricular potentials, signal averaged ECG, electrocardiography, colchicine Introduction Familial Mediterranean fever (FMF) is the most common inherited periodic autoinflammatory illness, affect- ing a patient population estimated at 120,000 worldwide, mostly of a Mediterranean origin (1, 2).
    [Show full text]
  • Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: the Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
    Diabetes Volume 65, July 2016 1767 Changting Xiao,1 Satya Dash,1 Cecilia Morgantini,1 Robert A. Hegele,2 and Gary F. Lewis1 Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol Diabetes 2016;65:1767–1778 | DOI: 10.2337/db16-0046 Notwithstanding the effectiveness of lowering LDL cho- has been the primary goal of dyslipidemia management, lesterol, residual CVD risk remains in high-risk popula- with statins as the treatment of choice for CVD prevention. tions, including patients with diabetes, likely contributed Large-scale, randomized, clinical trials of LDL-lowering PERSPECTIVES IN DIABETES to by non-LDL lipid abnormalities. In this Perspectives therapies have demonstrated significant reduction in CVD in Diabetes article, we emphasize that changing demo- events over a wide range of baseline LDL-C levels (2,3). graphics and lifestyles over the past few decades have However, even with LDL-C levels lowered substantially or “ resulted in an epidemic of the atherogenic dyslipidemia at treatment goals with statin therapy, CVD risks are not ” complex, the main features of which include hypertrigly- eliminated and there remains significant “residual risk.” In- ceridemia, low HDL cholesterol levels, qualitative changes tensifying statin therapy may provide additional benefits in LDL particles, accumulation of remnant lipoproteins, (4,5); this approach, however, has limited potential, owing and postprandial hyperlipidemia. We brieflyreviewthe to tolerability, side effects, and finite efficacy. Further LDL-C underlying pathophysiology of this form of dyslipidemia, lowering may also be achieved with the use of nonstatin in particular its association with insulin resistance, obe- sity, and type 2 diabetes, and the marked atherogenicity agents, such as cholesterol absorption inhibitors and PCSK9 of this condition.
    [Show full text]
  • Difference Between Dyslipidemia and Hyperlipidemia Key Difference – Dyslipidemia Vs Hyperlipidemia
    Difference Between Dyslipidemia and Hyperlipidemia www.differenebetween.com Key Difference – Dyslipidemia vs Hyperlipidemia Dyslipidemia and hyperlipidemia are two medical conditions that affect the lipid levels of the body. Any deviation of the lipid level of the body from the normal and clinically appropriate values is identified as dyslipidemia. Hyperlipidemia is a form of dyslipidemia where the lipid levels are abnormally elevated. The key difference between dyslipidemia and hyperlipidemia is that dyslipidemia refers to any abnormality in the lipid levels whereas hyperlipidemia refers to an abnormal elevation in the lipid level. What is Dyslipidemia? Any abnormality in the lipid levels of the body is identified as dyslipidemia. Different forms of dyslipidemia include Hyperlipidemia Hypolipidemia Lipid levels of the body are abnormally reduced in this condition. Severe protein energy malnutrition, severe malabsorption, and intestinal lymphangiectasia are the causes. Hypolipoproteinemia This disease is caused by genetic or acquired causes. The familial form of hypolipoproteinemia is asymptomatic and does not require treatments. But there are some other forms of this condition which are extremely severe. Genetic disorders associated with this condition are, Abeta lipoproteinemia Familial hypobetalipoproteinemia Chylomicron retention disease Lipodystrophy Lipomatosis Dyslipidemia in pregnancy What is Hyperlipidemia? Hyperlipidemia is a form of dyslipidemia that is characterized by abnormally elevated lipid levels. Primary Hyperlipidemia Primary hyperlipidemias are due to a primary defect in the lipid metabolism. Classification Disorders of VLDL and chylomicrons- hypertriglyceridemia alone The commonest cause of these disorders is the genetic defects in multiple genes. There is a modest increase in the VLDL level. Disorders of LDL- hypercholesterolemia alone There are several subgroups of this category Heterozygous Familial Hypercholesterolemia This is a fairly common autosomal dominant monogenic disorder.
    [Show full text]